{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT02912559","nct_id":"NCT02912559","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02912559. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.","label":"Arm I (combination chemotherapy, atezolizumab)","type":"EXPERIMENTAL"},{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.","label":"Arm II (combination chemotherapy)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12-18","type":"ESTIMATED"},"conditions":["Colon Adenocarcinoma","DNA Repair Disorder","Lynch Syndrome","Stage III Colon Cancer AJCC v8"],"enrollment":{"count":712,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Leucovorin Calcium","type":"DRUG"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"}],"last_update":"2026-10-01","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-02-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS)","timeFrame":"3 years"}],"references":[{"citation":"Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26;394(12):1155-1166. doi: 10.1056/NEJMoa2507874.","pmid":"41880612","type":"DERIVED"},{"citation":"Langenfeld SJ, Raman S, Gribovskaja-Rupp I. Selected Abstracts. Dis Colon Rectum. 2025 Oct 1;68(10):1224-1230. doi: 10.1097/DCR.0000000000003879. Epub 2025 Jul 9. No abstract available.","pmid":"40953502","type":"DERIVED"}],"start_date":{"date":"2017-10-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","url":"https://clinicaltrials.gov/study/NCT02912559"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02912559"}